Rituxan Sales Data
| Rank 11 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Rituxan U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 11 | $794,464 | 1.98% | 560 | 1.82% |
| Q4 2012 | 11 | $779,026 | 0.72% | 550 | -1.26% |
| Q3 2012 | 11 ( 1) |
$773,460 | -5.61% | 557 | -3.30% |
| Q2 2012 | 12 (3) |
$819,418 | 8.26% | 576 | 5.30% |
| Q1 2012 | 15 ( 1) |
$756,875 | -1.91% | 547 | -0.91% |
| Q4 2011 | 14 (2) |
$771,622 | 6.96% | 552 | 4.74% |
| Q3 2011 | 16 | $721,408 | -1.77% | 527 | -1.86% |
| Q2 2011 | 16 (4) |
$734,378 | 7.26% | 537 | 5.09% |
| Q1 2011 | 20 | $684,666 |  |
511 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| February 19, 2010 | Rituxan Approved for Chronic Lymphocytic Leukemia |
| February 19, 2010 | Roche's Rituxan Gets US OK For Another Cancer |
| November 25, 2009 | Type 1 Diabetes May Have a New Foe |
| November 19, 2009 | Genentech, Biogen Get FDA Request on Rituxan |
| October 23, 2009 | Rituxan (rituximab) - Third case of PML reported, the first case of PML in a patient with rheumatoid arthritis treated with Rituxan who has not previously received treatment with a TNF antagonist |
| March 13, 2009 | Cancer Drug May Offer New Hope for Lupus Patients |
